Lorenzo Gerratana, Associate Professor of Medicine and Scientific Lead for Breast Medical Oncology at the CRO Aviano National Cancer Institute and the University of Udine, shared a post on LinkedIn:
“Proud to share our new publication from the MAGNETIC.1 study.
In this ancillary analysis, we explored ctDNA-based epigenetic and fragmentomic dynamics over time across CDK4/6i. While clinical outcomes between treatment groups were not statistically different, we observed treatment-specific patterns that suggest an early signal of different adaptive behaviors under therapy.
MAGNETIC.1 was designed back in 2014, when ctDNA was still in its early infancy.
What started as a bold idea became reality thanks to the resilience, vision, and motivation of an extraordinary team and outstanding academic and industry partners.
MAGNETIC.1 is not the end of the story: the best is yet to come with the RETRACE program and MAGNETIC.2, which will bring MAGNETIC once again to the bleeding edge of translational oncology.”
Title: Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2– metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study
Authors: Claudia Noto, Lorenzo Foffano, Fabiola Giudici, Elisabetta Molteni, Alessandra Franzoni, Martina Tessitori, Linda Cucciniello, Silvia Bolzonello, Lucia Da Ros, Lucia Bortot, Elena Scudeler, Brenno Pastò, Giulia Cudia, Serena Della Rossa, Marta Bonotto, Alessandro Marco Minisini, Giuseppe Damante, Barbara Belletti, Lorenzo Gerratana, Fabio Puglisi
Read The Full Article
Other articles featuring ctDNA on OncoDaily.